NCT06460454Completed
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing on Chemotherapy, Treated With 177 Lu-PSMA (PROFLu)D7 (± 1 Day)
Source: ClinicalTrials.gov · Last updated 4 Mar 2025
Brief summary (registry, in English)
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 11 Jun 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Prostate cancer
- NCT number
- NCT06460454
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Nov 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who did not give their consent to use their data retrospectively
Who the study is looking for
- Patients treated with 177Lu-PSMA for castration-resistant prostate cancer at Nancy University Hospital
- Patients with 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuclear medicine Department CHRU de NANCY Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.